Azathioprine for multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 2, 2009, Pages 131-132

  Casetta, I ^a   Iuliano, G ^b   Filippini, G ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b Hospital of Salerno   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BONE MARROW SUPPRESSION; CASE CONTROL STUDY; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 60249099406     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.144972     Document Type: Article

References (2)

1. Higgins JPT, Green S, eds. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005); section 6. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons Ltd, 2005.
2. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46:1607-12.